BioSpace News Archive

An INRS team is developing a treatment combining fruit extracts and irradiation to prevent outbreaks of foodborne infections

Orbis and partners in the Vision 4 Africa consortium among high-scoring 100&Change applications featured in Bold Solutions Network

Aphena Pharma Solutions Inc. has announced the expansion of its bottling capacity with the purchase of a new, state-of-the-art, high-speed, solid-dose bottling line with an integrated cartoner.

Scientists from the U.S. Department of Energy’s Argonne National Laboratory and the University of Chicago entangled photons across a 52-mile network in the Chicago suburbs, an important step in developing a national quantum internet..

Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin to optimize treatment for people living with diabetes, today announced positive results from its Phase 2 OPTI-1 study of injectable hepatocyte directed vesicle (HDV) added to mealtime insulin in people with type 1 diabetes (T1D).

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services will be sponsoring and attending the 16th Academia Next Generation Precision Oncology Symposium at Moore’s Cancer Center at the University of California San Diego in La Jolla, California.

Viz.ai’s comprehensive synchronized stroke care platform, the most technologically advanced to be exhibited at the International Stroke Conference 2020 in Los Angeles

The American Pharmacists Association announced that former Board of Trustee member Daniel Buffington, PharmD, MBA, will be the first pharmacist to serve as a member of the American Medical Association’s Current Procedural Terminology Editorial Panel.

Zotec Partners, one of the country’s largest, privately-held, technology-enabled revenue cycle management companies for healthcare providers and their patients, has made the list as one of the Best Places to Work in Indiana.

InDex Pharmaceuticals Holding AB (publ) today announced the conclusions from in-depth analysis of the complete data set from the phase IIb dose optimisation study CONDUCT, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis.